References
- Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195–8
- Genant HK, Baylink DJ, Gallagher JC, Harris ST, Steiger P, Herber M. Effect of estrone sulfate on postmenopausal bone loss. Obstet Gynecol 1990;76:579–84
- Rossouw JE, Anderson GL, Prentice RL, . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Anderson GL, Limacher M, Assaf AR, . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
- Cauley JA, Robbins J, Chen Z, . Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729–38
- Jackson RD, Wactawski-Wende J, LaCroix AZ, . Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial. J Bone Miner Res 2006;21:817–28
- Freedman L, Anderson G, Kipnis V, . Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. Controlled Clin Trials 1996;17:509–25
- Freedman L, Anderson G, Kipnis V, . Guidelines for the statistical monitoring of the Women's Health Initiative clinical trial. West J Med 1998;168:236–40
- Anderson GL. WHI results withstand the test of time. Br Med J 2010; rapid response 12 March
- Cummings SR, Black DM, Thompson DE, . Effect of alendronate on the risk of fracture in women with low bone density but without vertebral fracture: results from Fracture Intervention Trial. JAMA 1998;280:2077–82
- Ettinger B, Black DM, Mitlak BH, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637–45
- Kado DM, Browner WS, Palermo L, . Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1998;159: 1215–20
- LaCroix AZ, Chlebowski RT, Manson JE, . Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–14
- Stevenson JC. Prevention of osteoporosis; one step forward, two steps back. Menopause Int 2011;17:137–41
- Stevenson JC on behalf of the International Consensus Group on HRT and Regulatory Issues. HRT, osteoporosis and regulatory authorities. Quis custodiet ipsos custodes? Hum Reprod 2006;21: 1668–71
- Studd J. Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. Climacteric 2009;12:206–9
- Pines A, Sturdee DW, Birkhäuser MH, . IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181–94